▶ 調査レポート

増殖糖尿病網膜症の世界市場分析・規模・シェア・成長・動向・予測:薬剤分類別(VEGF阻害剤、副腎皮質ステロイド)、投与経路別(注射、経口、吸入、その他)、流通経路別(病院、薬局、小売薬局、オンライン薬局)

• 英文タイトル:Proliferative Diabetic Retinopathy Market (Drug Class - Anti-VEGF Agents, and Corticosteroids; Mode of Administration - Injectables, Oral, and Others; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2026

Transparency Market Researchが調査・発行した産業分析レポートです。増殖糖尿病網膜症の世界市場分析・規模・シェア・成長・動向・予測:薬剤分類別(VEGF阻害剤、副腎皮質ステロイド)、投与経路別(注射、経口、吸入、その他)、流通経路別(病院、薬局、小売薬局、オンライン薬局) / Proliferative Diabetic Retinopathy Market (Drug Class - Anti-VEGF Agents, and Corticosteroids; Mode of Administration - Injectables, Oral, and Others; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2026 / TPM-B04234資料のイメージです。• レポートコード:TPM-B04234
• 出版社/出版日:Transparency Market Research / 2018年3月
• レポート形態:英文、PDF、170ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥625,860 (USD5,795)▷ お問い合わせ
  Multi User¥949,860 (USD8,795)▷ お問い合わせ
  Global Site License¥1,273,860 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、増殖糖尿病網膜症の世界市場について調べ、増殖糖尿病網膜症の世界規模、市場動向、市場環境、薬剤分類別(VEGF阻害剤、副腎皮質ステロイド)分析、投与経路別(注射、経口、吸入、その他)分析、流通経路別(病院、薬局、小売薬局、オンライン薬局)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。
・序文・調査範囲・調査手法
・エグゼクティブサマリー
・増殖糖尿病網膜症の世界市場動向
・増殖糖尿病網膜症の世界市場環境
・増殖糖尿病網膜症の世界市場規模
・増殖糖尿病網膜症の世界市場規模:薬剤分類別(VEGF阻害剤、副腎皮質ステロイド)
・増殖糖尿病網膜症の世界市場規模:投与経路別(注射、経口、吸入、その他)
・増殖糖尿病網膜症の世界市場規模:流通経路別(病院、薬局、小売薬局、オンライン薬局)
・増殖糖尿病網膜症の世界市場:地域別市場規模・分析
・増殖糖尿病網膜症の北米市場規模・予測
・増殖糖尿病網膜症のアメリカ市場規模・予測
・増殖糖尿病網膜症の中南米市場規模・予測
・増殖糖尿病網膜症のヨーロッパ市場規模・予測
・増殖糖尿病網膜症のアジア市場規模・予測
・増殖糖尿病網膜症の日本市場規模・予測
・増殖糖尿病網膜症の中国市場規模・予測
・増殖糖尿病網膜症のインド市場規模・予測
・増殖糖尿病網膜症のアフリカ市場規模・予測
・競争状況・関連企業情報

Proliferative diabetic retinopathy prevails as leading cause of blindness across industrialized countries worldwide. Although remarkable advancements have been made in the diagnosis and treatment of the disease, several imperative management questions as well as treatment deficiencies continue to persist unanswered. The diabetic pandemic has threatened overwhelming resources and increasing incidences of blindness, which in turn has necessitated the development of actionable programs for diagnosis and treatment of the disease as well as the diseases caused as a consequence of diabetes such as proliferative diabetic retinopathy.

The global proliferative diabetic retinopathy market has been thoroughly analyzed in the latest research report developed by Transparency Market Research, which issues in-depth insights on prominent factors impacting growth of the market. Growth prospects offered in the report are assessed for the period between 2017 and 2026, and the historical analysis on the market has been delivered for the period between 2012 and 2016.

The report issues analysis on key threats, opportunities, restrains and drivers of the proliferative diabetic retinopathy market’s growth, coupled with in-depth study on their likely influences on the market. Valuable qualitative information offered in the report can enable readers in acquiring a thorough understanding of impactful market dynamics. Apart from a comprehensive analysis on influential market dynamics, the report also encompasses the raw material sourcing strategies, pricing analysis, cost structure, and supply chain analysis on the global proliferative diabetic retinopathy market.

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

The report comprises a detailed segmentation-wise analysis on the global proliferative diabetic retinopathy market, which provides readers with better understanding about lucrative and sluggish avenues for the market expansion. The global market for proliferative diabetic retinopathy has been assessed across a range of segments viz. drug class, mode of administration, distribution channel, and region. Geographically, the market has been branched into Asia-Pacific excluding Japan, Latin America, Japan, Middle East & Africa, Europe, and North America.

TMR’s report on the global proliferative diabetic retinopathy market is expected to be beneficial for proliferative diabetic retinopathy drug manufacturers, as existing players can leverage the intelligence offered for making better business decisions. Players evaluating a market entry will gain necessary insights through this report. This report is expected to serve as pragmatic and comprehensive source of knowledge and insights, which will help key stakeholders to formulate their future business plans.

Detailed Assessment of Competition Landscape & Exhaustive Research Methodology

The report also encompasses an exhaustive chapter on the proliferative diabetic retinopathy market’s competition landscape, which gives a detailed profiling of key companies that offer significant contribution to the market growth. Along with in-depth discussion and analysis on the business and product development strategies of the market players comprised, the report also sheds light on financial performance of these companies, coupled with their recent developments over the past couple of years. This concluding chapter of the report is of high value to the report readers, as they can attain actionable insights on novel developmental and growth strategies employed by the market players. This will further help them in gauging their respective positioning in this highly competitive market.

レポート目次

1. Global Economic Outlook

2. Global Proliferative Diabetic Retinopathy Market – Executive Summary

3. Global Proliferative Diabetic Retinopathy Market Overview
3.1. Introduction
3.1.1. Global Proliferative Diabetic Retinopathy Market Taxonomy
3.1.2. Global Proliferative Diabetic Retinopathy Market Definition
3.2. Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) and Forecast, 2012-2026
3.2.1. Global Proliferative Diabetic Retinopathy Market Y-o-Y Growth
3.3. Global Proliferative Diabetic Retinopathy Market Dynamics
3.4. Supply Chain
3.5. Cost Structure
3.6. Average Pricing Analysis
3.7. Forecast Scenario
3.8. Parent Market Overview
3.9. Product Approvals in Proliferative Diabetic Retinopathy
3.10. PATENT Analysis
3.11. Porter’s Five Forces Analysis
3.12. Epidemiology
3.13. Investment Feasibility Index
3.14. Market Competition Structure
3.15. PEST Analysis
3.16. Market Positioning & Behavior Assessment
3.17. List of Distributors
3.18. Key Participants Market Presence (Intensity Map) By Region

4. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast 2012-2026
4.1. Global Proliferative Diabetic Retinopathy Market Size and Forecast By Drug Class, 2012-2026
4.1.1. Anti-VEGF Agents Market Size and Forecast, 2012-2026
4.1.1.1. Revenue (US$ Mn) Comparison, By Region
4.1.1.2. Market Share Comparison, By Region
4.1.1.3. Y-o-Y growth Comparison, By Region
4.1.2. Corticosteroids Market Size and Forecast, 2012-2026
4.1.2.1. Revenue (US$ Mn) Comparison, By Region
4.1.2.2. Market Share Comparison, By Region
4.1.2.3. Y-o-Y growth Comparison, By Region
4.2. Global Proliferative Diabetic Retinopathy Market Size and Forecast By Mode of Administration, 2012-2026
4.2.1. Injectables Market Size and Forecast, 2012-2026
4.2.1.1. Revenue (US$ Mn) Comparison, By Region
4.2.1.2. Market Share Comparison, By Region
4.2.1.3. Y-o-Y growth Comparison, By Region
4.2.2. Oral Market Size and Forecast, 2012-2026
4.2.2.1. Revenue (US$ Mn) Comparison, By Region
4.2.2.2. Market Share Comparison, By Region
4.2.2.3. Y-o-Y growth Comparison, By Region
4.2.3. Others Market Size and Forecast, 2012-2026
4.2.3.1. Revenue (US$ Mn) Comparison, By Region
4.2.3.2. Market Share Comparison, By Region
4.2.3.3. Y-o-Y growth Comparison, By Region
4.3. Global Proliferative Diabetic Retinopathy Market Size and Forecast By Distribution Channel, 2012-2026
4.3.1. Hospital Pharmacies Market Size and Forecast, 2012-2026
4.3.1.1. Revenue (US$ Mn) Comparison, By Region
4.3.1.2. Market Share Comparison, By Region
4.3.1.3. Y-o-Y growth Comparison, By Region
4.3.2. Retail Pharmacies Market Size and Forecast, 2012-2026
4.3.2.1. Revenue (US$ Mn) Comparison, By Region
4.3.2.2. Market Share Comparison, By Region
4.3.2.3. Y-o-Y growth Comparison, By Region
4.3.3. Online Pharmacies Market Size and Forecast, 2012-2026
4.3.3.1. Revenue (US$ Mn) Comparison, By Region
4.3.3.2. Market Share Comparison, By Region
4.3.3.3. Y-o-Y growth Comparison, By Region

5. North America Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
5.1. North America Outlook
5.2. North America Parent Market Outlook
5.3. North America Target Market Outlook
5.4. Revenue (US$ Mn) Comparison, By Country
5.4.1. US Market Size and Forecast (US$ Mn), 2012-2026
5.4.2. Canada Market Size and Forecast (US$ Mn), 2012-2026
5.5. Revenue (US$ Mn) Comparison, By Drug Class
5.6. Revenue (US$ Mn) Comparison, By Mode of Administration
5.7. Revenue (US$ Mn) Comparison, By Distribution Channel

6. Latin America Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
6.1. Latin America Outlook
6.2. Latin America Parent Market Outlook
6.3. Latin America Target Market Outlook
6.4. Revenue (US$ Mn) Comparison, By Country
6.4.1. Brazil Market Size and Forecast (US$ Mn), 2012-2026
6.4.2. Mexico Market Size and Forecast (US$ Mn), 2012-2026
6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2012-2026
6.5. Revenue (US$ Mn) Comparison, By Drug Class
6.6. Revenue (US$ Mn) Comparison, By Mode of Administration
6.7. Revenue (US$ Mn) Comparison, By Distribution Channel

7. Europe Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
7.1. Europe Outlook
7.2. Europe Parent Market Outlook
7.3. Europe Target Market Outlook
7.4. Revenue (US$ Mn) Comparison, By Country
7.4.1. Germany Market Size and Forecast (US$ Mn), 2012-2026
7.4.2. U.K. Market Size and Forecast (US$ Mn), 2012-2026
7.4.3. Spain Market Size and Forecast (US$ Mn), 2012-2026
7.4.4. France Market Size and Forecast (US$ Mn), 2012-2026
7.4.5. Italy Market Size and Forecast (US$ Mn), 2012-2026
7.4.6. Rest of Europe Market Size and Forecast (US$ Mn), 2012-2026
7.5. Revenue (US$ Mn) Comparison, By Drug Class
7.6. Revenue (US$ Mn) Comparison, By Mode of Administration
7.7. Revenue (US$ Mn) Comparison, By Distribution Channel

8. Japan Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
8.1. Japan Outlook
8.2. Japan Parent Market Outlook
8.3. Japan Target Market Outlook
8.4. Japan Market Size and Forecast (US$ Mn), 2012-2026
8.5. Revenue (US$ Mn) Comparison, By Drug Class
8.6. Revenue (US$ Mn) Comparison, By Mode of Administration
8.7. Revenue (US$ Mn) Comparison, By Distribution Channel

9. APEJ Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
9.1. APEJ Outlook
9.2. APEJ Parent Market Outlook
9.3. APEJ Target Market Outlook
9.4. Revenue (US$ Mn) Comparison, By Country
9.4.1. China Market Size and Forecast (US$ Mn), 2012-2026
9.4.2. India Market Size and Forecast (US$ Mn), 2012-2026
9.4.3. Malaysia Market Size and Forecast (US$ Mn), 2012-2026
9.4.4. Singapore Market Size and Forecast (US$ Mn), 2012-2026
9.4.5. Australia Market Size and Forecast (US$ Mn), 2012-2026
9.4.6. Rest of APEJ Market Size and Forecast (US$ Mn), 2012-2026
9.5. Revenue (US$ Mn) Comparison, By Drug Class
9.6. Revenue (US$ Mn) Comparison, By Mode of Administration
9.7. Revenue (US$ Mn) Comparison, By Distribution Channel

10. MEA Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
10.1. MEA Outlook
10.2. MEA Parent Market Outlook
10.3. MEA Target Market Outlook
10.4. Revenue (US$ Mn) Comparison, By Country
10.4.1. GCC Countries Market Size and Forecast (US$ Mn), 2012-2026
10.4.2. South Africa Market Size and Forecast (US$ Mn), 2012-2026
10.4.3. Israel Market Size and Forecast (US$ Mn), 2012-2026
10.4.4. Rest of MEA Market Size and Forecast (US$ Mn), 2012-2026
10.5. Revenue (US$ Mn) Comparison, By Drug Class
10.6. Revenue (US$ Mn) Comparison, By Mode of Administration
10.7. Revenue (US$ Mn) Comparison, By Distribution Channel

11. Global Proliferative Diabetic Retinopathy Market Company Share, Competition Landscape and Company Profiles
11.1. Global Proliferative Diabetic Retinopathy Market – Company Share Analysis
11.2. Global Proliferative Diabetic Retinopathy Market – Competition Landscape
11.3. Global Proliferative Diabetic Retinopathy Market – Company Profiles
11.3.1. Genentech, Inc. (Roche Holdings)
11.3.2. Novartis AG
11.3.3. Regeneron Pharmaceuticals, Inc.
11.3.4. Pfizer, Inc.
11.3.5. Merck KGaA
11.3.6. Cipla, Ltd.
11.3.7. Allergan Plc
11.3.8. Valeant Pharmaceuticals International, Inc.
11.3.9. Santen Pharmaceutical Co., Ltd.
11.3.10. Alimera Sciences, Inc.
11.3.11. Intas Pharmaceuticals Limited

12. Global Proliferative Diabetic Retinopathy Market – Key Takeaways

13. Research Methodology

14. Disclaimer

List of Table

TABLE 1 Global Proliferative Diabetic Retinopathy Market Value (US$ Mn), 2012-2017
TABLE 2 Global Proliferative Diabetic Retinopathy Market Value (US$ Mn), 2018-2026
TABLE 3 Global Proliferative Diabetic Retinopathy Market Value (US$ Mn) and Y-o-Y, 2017-2026
TABLE 4 Global Anti-VEGF Agents Segment Value (US$ Mn), By Region 2012-2017
TABLE 5 Global Anti-VEGF Agents Segment Value (US$ Mn), By Region 2018-2026
TABLE 6 Global Anti-VEGF Agents Segment Market Share, By Region 2012-2017
TABLE 7 Global Anti-VEGF Agents Segment Market Share, By Region 2018-2026
TABLE 8 Global Anti-VEGF Agents Segment Y-o-Y, By Region 2017-2026
TABLE 9 Global Corticosteroids Segment Value (US$ Mn), By Region 2012-2017
TABLE 10 Global Corticosteroids Segment Value (US$ Mn), By Region 2018-2026
TABLE 11 Global Corticosteroids Segment Market Share, By Region 2012-2017
TABLE 12 Global Corticosteroids Segment Market Share, By Region 2018-2026
TABLE 13 Global Corticosteroids Segment Y-o-Y, By Region 2017-2026
TABLE 14 Global Injectables Segment Value (US$ Mn), By Region 2012-2017
TABLE 15 Global Injectables Segment Value (US$ Mn), By Region 2018-2026
TABLE 16 Global Injectables Segment Market Share, By Region 2012-2017
TABLE 17 Global Injectables Segment Market Share, By Region 2018-2026
TABLE 18 Global Injectables Segment Y-o-Y, By Region 2017-2026
TABLE 19 Global Oral Segment Value (US$ Mn), By Region 2012-2017
TABLE 20 Global Oral Segment Value (US$ Mn), By Region 2018-2026
TABLE 21 Global Oral Segment Market Share, By Region 2012-2017
TABLE 22 Global Oral Segment Market Share, By Region 2018-2026
TABLE 23 Global Oral Segment Y-o-Y, By Region 2017-2026
TABLE 24 Global Others Segment Value (US$ Mn), By Region 2012-2017
TABLE 25 Global Others Segment Value (US$ Mn), By Region 2018-2026
TABLE 26 Global Others Segment Market Share, By Region 2012-2017
TABLE 27 Global Others Segment Market Share, By Region 2018-2026
TABLE 28 Global Others Segment Y-o-Y, By Region 2017-2026
TABLE 29 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 30 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 31 Global Hospital Pharmacies Segment Market Share, By Region 2012-2017
TABLE 32 Global Hospital Pharmacies Segment Market Share, By Region 2018-2026
TABLE 33 Global Hospital Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 34 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 35 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 36 Global Retail Pharmacies Segment Market Share, By Region 2012-2017
TABLE 37 Global Retail Pharmacies Segment Market Share, By Region 2018-2026
TABLE 38 Global Retail Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 39 Global Online Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 40 Global Online Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 41 Global Online Pharmacies Segment Market Share, By Region 2012-2017
TABLE 42 Global Online Pharmacies Segment Market Share, By Region 2018-2026
TABLE 43 Global Online Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 44 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
TABLE 45 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
TABLE 46 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 47 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 48 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 49 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 50 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 51 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 52 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
TABLE 53 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
TABLE 54 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 55 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 56 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 57 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 58 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 59 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 60 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
TABLE 61 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
TABLE 62 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 63 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 64 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 65 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 66 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 67 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 68 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
TABLE 69 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
TABLE 70 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 71 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 72 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 73 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 74 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 75 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 76 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
TABLE 77 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
TABLE 78 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 79 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 80 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 81 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 82 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 83 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 84 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
TABLE 85 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
TABLE 86 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 87 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 88 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 89 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 90 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 91 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026